Matthias Luke
Overview
Explore the profile of Matthias Luke including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
530
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gniesmer S, Grisanti S, Kakkassery V, Lommatzsch C, Luke J, Luke M, et al.
Ophthalmologie
. 2022 Nov;
120(5):538-544.
PMID: 36445474
Background: Due to the corona pandemic, face-to-face teaching was no longer permitted in the summer semester 2020 and online alternatives were quickly found. Objective: In our article, we illustrate the...
2.
Mohi A, Gniesmer S, Ranjbar M, Kakkassery V, Grisanti S, Neppert B, et al.
Ophthalmologe
. 2021 Mar;
118(7):652-658.
PMID: 33655369
Background: The corona pandemic has led to short-term adjustments of the procedures in medical courses. In many departments classroom teaching was no longer possible so that it was necessary to...
3.
Reinsberg M, Hilgers R, Ludeke I, Nassar K, Grisanti S, Grisanti S, et al.
Clin Ophthalmol
. 2017 Apr;
11:621-629.
PMID: 28435212
Purpose: To investigate the clinical value of multifocal electroretinography (mfERG) and microperimetry and the effects of intravitreal therapy with ranibizumab (Lucentis) on macular function in the course of neovascular age-related...
4.
Ranjbar M, Schneider T, Brand C, Grisanti S, Luke J, Luke M
J Curr Ophthalmol
. 2017 Apr;
29(1):69-71.
PMID: 28367532
Purpose: Blockage of the interleukin 1 (IL-1) signaling pathway has been proposed for treatment of inflammatory disorders like those affecting the retina and its adjacent tissue. Herein, we evaluated one...
5.
Tura A, Alt A, Luke J, Grisanti S, Haritoglou C, Meyer C, et al.
Clin Ophthalmol
. 2016 Aug;
10:1435-45.
PMID: 27536056
Purpose: To examine the viability and differentiation of retinal pigment epithelial (RPE) cells after exposure to the vital dye Acid Violet-17 (AV-17). Methods: Bovine RPE cells were incubated with AV-17...
6.
Tura A, Merz H, Reinsberg M, Luke M, Jager M, Grisanti S, et al.
Pigment Cell Melanoma Res
. 2016 Jul;
29(5):583-9.
PMID: 27390171
Monosomy-3 in primary uveal melanoma (UM) is associated with a high risk of metastasis and mortality. Although circulating melanoma cells (CMC) can be found in most UM patients, only approximately...
7.
Luke J, Vukoja V, Brandenbusch T, Nassar K, Rohrbach J, Grisanti S, et al.
BMC Ophthalmol
. 2016 Jun;
16:74.
PMID: 27255356
Background: Extracellular matrix remodelling regulated by matrix-metalloproteinase (MMP) inducer (CD147) is a crucial process during tumor cell invasion and regulation of blood supply. In this study, we evaluated the correlation...
8.
Stenzel M, Tura A, Nassar K, Rohrbach J, Grisanti S, Luke M, et al.
Clin Exp Ophthalmol
. 2015 Nov;
44(5):400-9.
PMID: 26590370
Background: To evaluate the regulation of blood supply in primary uveal melanomas through caveolin-1 (Cav-1)/phosphoinositol-3 kinase (PI3K). Methods: The expression of Cav-1 and PI3K was analysed in 51 paraffin sections...
9.
Siapich S, Akhtar I, Hescheler J, Schneider T, Luke M
Graefes Arch Clin Exp Ophthalmol
. 2015 Jun;
253(10):1713-9.
PMID: 26104874
Background: The model of the isolated and superfused retina provides the opportunity to test drugs and toxins. Some chemicals have to be applied using low concentrations of organic solvents as...
10.
Ranjbar M, Schneider T, Brand C, Grisanti S, Luke J, Luke M
Ophthalmic Res
. 2015 Feb;
53(3):136-40.
PMID: 25720991
Background: Disease-modifying antirheumatic drugs (DMARDs) have been suggested in the treatment of inflammatory ophthalmological diseases. The aim of the present study was to investigate the effects of these DMARDs on...